top of page
Targeting angiogenesis for disease therapy: Approaching clinical issues of cardiovascular disease
We focus our research on angiogenesis, the process of new blood vessel growth, which is involved in onset and progression of most common human diseases including cardiovascular disease, cancer, obesity, diabetes, and eye disease. Our research programs emphasize translation from basic discovery to clinical implication aiming for development of new concepts and paradigms for disease diagnosis and therapy. In this lecture, I discuss new mechanistic insights into implication of angiogenesis for treating cardiovascular disease with emphasis of establishing functional networks in the ischemic myocardium.
Yihai Cao is a professor at the Karolinska Institutet, Stockholm, Sweden. He is a member of Chinese Academy of Engineering, Academy of Europe, European Academy of Sciences and Arts, National Academy of Inventors (US), and American Institute of Medicine and Biological Engineering. Yihai Cao received his medical training from the Shandong Medical School and his Ph.D. from the Karolinska Institute. He received his postdoctoral training in Dr. Judah Folkman’s laboratory at the Harvard Medical School. Cao’s laboratory has focused their interests on studying angiogenesis in tumor growth, metastasis, and non-malignant diseases. Through mechanistic studies, he aims to define novel therapeutic targets and resolve clinically unmet demands of antiangiogenic cancer therapy by proposing new concepts and paradigms. His research interests include molecular mechanisms of pathological angiogenesis contributing to obesity, metabolic diseases, diabetic complications, cancer, metastasis, and cardiovascular diseases, with emphasis on clinical relevance and translational research. He received an honorary medical doctor degree (M.D.) from Copenhagen University, Denmark in 2006. He is a guest professor at the Linköping University, Sweden; a guest professor at the Leicester University, UK; an honorary professor at the Copenhagen University, Denmark; and an honorary professor at the Shinshu University Japan. He received the Fernström research prize, the Axel Hirsch Prize in medicine, and a distinguished professor award at the Karolinska Institutet. Dr. Cao received an ERC-advanced research grant award and the distinguished NOVO Nordisk-advanced grant award. He has published more than 250 research articles. The average impact factor (IF) of his publications > 12.1 per article. His scientific articles have been cited for more than 40 500 times. H-index = 100.
bottom of page